GAAD algorithm for early detection of hepatocellular carcinoma (HCC)
CompanyRoche Deutschland Holding GmbH, Mannheim, Germany
To optimize the early detection of hepatocellular carcinoma (HCC), Roche Deutschland Holding GmbH has developed the so-called GAAD algorithm. The method is suitable for patients who have been diagnosed with chronic liver disease and whose surveillance indicates an increased risk of HCC. For the risk assessment, two tumor biomarkers, Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein-induced by vitamin K absence), are first quantitatively determined in a serum or plasma sample and then combined with age and transmitted anonymously based on the patient's gender to the company's navify® Algorithm Suite. Here, the algorithm calculates a risk score between 0 and 10, which is assessed using a clinically validated cut-off. A value ≥ 2.57 indicates an increased risk of liver cancer and requires further diagnostic clarification. So far it has been shown that the method is able to detect early-stage HCC with a sensitivity of 78.9% (67.6% - 87.7%) and a specificity of 91.3% (86.7% - 94.8%) can be recognized with certainty. Overall, the GAAD algorithm offers a promising method for optimizing the early detection of liver cancer and can thereby help to improve the survival rates of HCC patients. By using tumor biomarkers, the age and gender of the patient, the algorithm can detect an increased risk of HCC with a high degree of certainty and shows significantly higher sensitivity compared to existing methods.
GAAD Algorithmus
www.roche.de
Added on: 02-08-2024
[1] https://www.roche.de/diagnostik/produkte-loesungen/digitale-loesungen/gaad-algorithmus
